Rhythm Pharmaceuticals (FRA:1RV) YoY EBITDA Growth : -159.55% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Rhythm Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Rhythm Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was -159.55%.

Rhythm Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2024 was €-2.08.

Rhythm Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Rhythm Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Pharmaceuticals YoY EBITDA Growth Chart

Rhythm Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

-62.23

30.78

50.83

-158.48

15.11

Rhythm Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															15.33	16.63	13.43	13.61	-159.55

Rhythm Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Rhythm Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-2.679	-	-3.156)	/	\| -3.156 \|
=	15.11 %

Rhythm Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-2.079	-	-0.801)	/	\| -0.801 \|
=	-159.55 %

Rhythm Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Rhythm Pharmaceuticals (FRA:1RV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (FRA:1RV) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

RYTM:USA RYTM:Mexico 1RV:Germany

Address

222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116

Website

http://www.rhythmtx.com

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.

Rhythm Pharmaceuticals (FRA:1RV) Headlines

No Headlines